Ambu A/s Class B · OMXCOP:AMBU_B
Ambu A/s Class B — Ambu A S Ord — FY2019/20 Earnings Presentation
24 slides from Ambu A/s Class B's earnings presentation, Nov 11, 2020
Slide 1: Investor presentation Full-year 2019/20 results
Investor presentation Full-year 2019/20 results
Slide 2: The world's most innovative single-use endoscopy player
The world’s most Business update innovative single-use Financial results and outlook endoscopy player Q&A Disclaimer Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s co
Slide 3: Unique market opportunity – rapid growth to USD 2.5bn
Unique market opportunity – rapid growth to USD 2.5bn Drivers creating the single-use endoscopy market Increased focus on contamination and I infection control from medical authorities 2020 2024 Convenience and compelling economic II offering making the transition from reusable USD ~0.5b USD +2.5b t
Slide 4: Uniquely positioned for market creation
Uniquely positioned for market creation Competitive advantages Global leader in single-use Visualization I with 10 years of experience 2016/17 2019/20 Modular innovation engine and high-scale DKK 597m DKK 1,711m II low-cost manufacturing driving richest Ambu Visualization Ambu Visualization pipeline
Slide 5: Business update
Business update 5
Slide 6: Key messages
Key messages 1 The single-use endoscopy market will continue to develop with a rapid pace The COVID-19 pandemic has accelerated the development of the single-use endoscopy market with healthcare systems increasing their focus on infection control and see single-use endoscopy as a solution Increa
Slide 7: The case for single-use endoscopy continues to strengthen
1 The case for single-use endoscopy continues to strengthen INCREASED FOCUS ON UPDATED GUIDELINES FROM FDA INFECTION CONTROL AND NATIONAL ASSOCIATIONS Patient safety organization, ERCI1 has 2nd FDA safety communication recommending listed ”Device Cleaning, Disinfection, transition to duodenoscopes w
Slide 8: Improving market conditions in Anaesthesia and PMD
2 Improving market conditions in Anaesthesia and PMD Organic Core growth of -1% in 2019/20 Core (Anaesthesia and PMD), quarterly revenue ▪ At the end of 2019/20, Core revenue is back at DKKm pre-COVID levels 600 503 ▪ A high demand for resuscitators to treat COVID-19 500 470 475 408 Average patients
Slide 9: High double-digit Visualization growth across all geographies
2 High double-digit Visualization growth across all geographies Organic Visualization growth of 81% in 2019/20 Endoscope units sold (‘000) ▪ With 1,085,000 endoscope sold in 2019/20 we consolidate our position as the largest manufacturer of single-use endoscopes 1,085 ▪ Since September 2019, our Vis
Slide 10: Expanding our presence in pulmonology and ENT
2 Expanding our presence in pulmonology and ENT Pulmonology highlights for 2019/20 ENT highlights for 2019/20 ▪ Market share of ~30% of the global OR and ICU ▪ Run-rate on ENT revenue in the U.S. has pulmonary endoscopy market increased by +60% from pre-COVID levels in February to September 2020 ▪ 5
Slide 11: Cystoscope holds strong promises of widespread adoption
2 Cystoscope holds strong promises of widespread adoption Highlights for aScope™ 4 Cysto 2019/20 Unit volume first 6 months, US market Promising results from U.S. controlled market study. aScope™ 3 Broncho aScope™ 4 Cysto can be used for all major aScope™ 4 RhinoLaryngo (ENT) cystoscopy procedures
Slide 12: U.S. product evaluations for aScope Cysto show promising results
2 U.S. product evaluations for aScope™ 4 Cysto show promising results The primary endpoint of procedural success was defined by the ability to complete all procedural aspects without using a secondary scope 65 32 high-profile physicians across 12 sites cystoscopy procedures utilized the aScope™ 4 Cy
Slide 13: Entering into GI with the launch of aScope Duodeno
2 Entering into GI with the launch of aScope™ Duodeno aScope™ Duodeno will be a major growth engine in 20/21 Controlled market release confirms adequate performance across ERCP procedures Expect rapid penetration of single-use duodenoscopy. U.S. GI commercial organization is 100% in place drivin
Slide 14: Building a unique and modular R&D engine
3 Building a unique and modular R&D engine Product Launch aView™ 2 Advance Commercially available Monitors aBox™ Console H2, 2020/21 Launches in 2019/20 aScope™ 4 Broncho aScope BronchoSampler™ VivaSight™ 80% increase in Ambu Pulmonology aScope™ 5 HD Q4, 2020/21 R&D organization aView™ 2 Advance aSc
Slide 15: 20 product launches planned for the next three years
3 20 product launches planned for the next three years Combination of next generation products and specialty scopes across existing segments 8 8 ~4x more products launches new new than in the previous three years products products 4 new 3 products new 2 products new products 0 new products 2017/18 2
Slide 16: Financial results and outlook
Financial results and outlook Disclaimer Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of the company to differ materially
Slide 17: Key financial results for full year 2019/20
Key financial results for full year 2019/20 26% 12% 1,085 Realized organic revenue EBIT margin Endoscopes sold Full year 2019/20 growth before special items (‘000 units) Guidance ~26% ~12% +1,000 Full year 2019/20 organic revenue EBIT margin Endoscopes sold growth before special items (‘000 units) •
Slide 18: Organic sales growth by geography
Organic sales growth by geography FY 2019/20 revenue and growth across regions Global North America 48% 22% 81% Visualization 71% Visualization 3,567m 26% Anaesthesia 1,594m 25% Anaesthesia organic 7% organic 8% DKK revenue growth DKK revenue growth -10% PMD -8% PMD 30% Europe Rest of World 96% Visu
Slide 19: Financial results Q4 and FY 2019/20
Financial results Q4 and FY 2019/20 Ambu P&L – Q4 and FY 2019/20 26% organic growth Impacted positively from COVID-19 and the Q4 Q4 Change Change FY FY Change Change transition to a direct sales model in U.S. DKKm 19/20 18/19 in value % 19/20 18/19 in value % Revenue 871 606 265 44% 3,567 2,820 747
Slide 20: Cash flow, assets and debt FY 2019/20
Cash flow, assets and debt FY 2019/20 Ambu cash flow and balance sheet – FY 2019/20 FY FY Change DKKm 2019/20 2018/19 in value DKK -133m free cash flow Cash flow and ratios Equal to -4% (10%) of Cash flow from operating activities 295 533 -238 12 months’ revenue Cash flow from investing activities b
Slide 21: 2020/21 Guidance
2020/21 Guidance 17-20% 11-12% 1.3-1.4 organic EBIT million endoscope growth margin units sold (before special items) Visualization will be the main growth driver with continuing high double-digit growth rates Anaesthesia and PMD growth is expected to exceed normal growth rates for these busines
Slide 22: Conference call Q&A
Q&A Conference call DK: +45 3544 5577 UK: +44 333 300 0804 US: +1 631 913 1422 PIN code: 35073451# Please limit your questions to only 3 at a time and get back into the queue if you For questions, please press 01 have additional questions 22
Slide 23: Investor contact information
Investor contact information Share Information Financial calendar Ambu A/S is listed on the stock exchange in 2020 Copenhagen under the symbol AMBU B 09 December Annual General Meeting 2019/20 For further company information, please visit: www.ambu.com For full list of Investor Relations events, ple
Slide 24: Ambu – The single-use company
Ambu – The single-use company